HRP20210960T1 - Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53 - Google Patents
Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53 Download PDFInfo
- Publication number
- HRP20210960T1 HRP20210960T1 HRP20210960TT HRP20210960T HRP20210960T1 HR P20210960 T1 HRP20210960 T1 HR P20210960T1 HR P20210960T T HRP20210960T T HR P20210960TT HR P20210960 T HRP20210960 T HR P20210960T HR P20210960 T1 HRP20210960 T1 HR P20210960T1
- Authority
- HR
- Croatia
- Prior art keywords
- membered
- cancer
- following
- compound according
- image
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000003003 spiro group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 37
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- -1 C16haloalkyl Chemical group 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 206010003571 Astrocytoma Diseases 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 208000009956 adenocarcinoma Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 208000000649 small cell carcinoma Diseases 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 101800000414 Corticotropin Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 3
- 229960000258 corticotropin Drugs 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000000824 cytostatic agent Substances 0.000 claims 3
- 230000001085 cytostatic effect Effects 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims 2
- 239000000854 Human Growth Hormone Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010036832 Prolactinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000017830 lymphoblastoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000010916 pituitary tumor Diseases 0.000 claims 2
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000007423 tubular adenocarcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000017234 Bone cyst Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006417 Bronchial carcinoma Diseases 0.000 claims 1
- 101100518413 Caenorhabditis elegans orc-2 gene Proteins 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 208000010126 Chondromatosis Diseases 0.000 claims 1
- 208000019591 Chondromyxoid fibroma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000033135 Classic hairy cell leukemia Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000004413 Eyelid Neoplasms Diseases 0.000 claims 1
- 206010050497 Eyelid tumour Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 201000008540 Gemistocytic astrocytoma Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000007666 Klatskin Tumor Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 206010024218 Lentigo maligna Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 206010029488 Nodular melanoma Diseases 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 208000000035 Osteochondroma Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000003761 Vaginal carcinoma Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 208000030317 anaplastic cancer Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000001011 carotid body Anatomy 0.000 claims 1
- 210000003321 cartilage cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000005217 chondroblastoma Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001198 duodenum Anatomy 0.000 claims 1
- 210000000959 ear middle Anatomy 0.000 claims 1
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005619 esophageal carcinoma Diseases 0.000 claims 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000008361 ganglioneuroma Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 208000018060 hilar cholangiocarcinoma Diseases 0.000 claims 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 claims 1
- 230000002871 immunocytoma Effects 0.000 claims 1
- 201000004933 in situ carcinoma Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000024312 invasive carcinoma Diseases 0.000 claims 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000000032 nodular malignant melanoma Diseases 0.000 claims 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 208000003388 osteoid osteoma Diseases 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 210000003254 palate Anatomy 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 210000003695 paranasal sinus Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 208000021481 subglottis benign neoplasm Diseases 0.000 claims 1
- 201000000124 subglottis neoplasm Diseases 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 208000030457 superficial spreading melanoma Diseases 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 210000001260 vocal cord Anatomy 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
Claims (36)
1. Spoj, naznačen time, da je predstavljen formulom (I)
[image]
,
u kojoj
--
R1 je skupina, opcionalno supstituirana s jednim ili više, istih ili različitih Rb1 i/ili Rc1, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C16haloalkil, C3-7cikloalkil, C47cikloalkenil, C6-10aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rb1 se neovisno bira između sljedećih: -ORc1, -NRc1Rc1, halogen, CN, C(O)Rc1, C(O)ORc1, C(O)NRc1Rc1, S(O)2Rc1, S(O)2NRc1Rc1, NHC(O)Rc1, N(C14alkil)C(O)Rc1 i bivalentni supstituent =O, dok =O može biti supstituent samo u nearomatskim sustavima prstena;
svaki Rc1 neovisno jedan od drugoga označava vodik ili skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rd1 i/ili Re1, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rd1 se neovisno bira između sljedećih: -ORe1, -NRe1Re1, halogen, CN, C(O)Re1, C(O)ORe1, C(O)NRe1Re1, S(O)2Re1, S(O)2NRe1Re1, NHC(O)Re1, N(C14alkil)C(O)Re1 i bivalentni supstituent =O, dok =O može biti supstituent samo u nearomatskim sustavima prstena;
svaki Re1 neovisno jedan od drugoga označava vodik ili skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rf1 i/ili Rg1, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rf1 se neovisno bira između sljedećih: -ORg1, -NRg1Rg1, halogen, CN, C(O)Rg1, C(O)ORg1, C(O)NRg1Rg1, S(O)2Rg1, S(O)2NRg1Rg1, NHC(O)Rg1, N(C14alkil)C(O)Rg1 i bivalentni supstituent =O, dok =O može biti supstituent samo u nearomatskim sustavima prstena;
svaki Rg1 se neovisno bira od sljedećih: vodik, C1-6alkil, C2-6alkenil, C26alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C6-10aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
--
jedan od R2 i R3 je vodik a drugi se bira između fenila i 5-članog do 6-članog heteroarila, pri čemu su navedeni fenil i 5člani do 6-člani heteroaril su opcionalno supstituirani s jednim ili više, istih ili različitih Rb2 i/ili Rc2;
svaki Rb2 se neovisno bira između sljedećih: -ORc2, -NRc2Rc2, halogen, CN, C(O)Rc2, C(O)ORc2, C(O)NRc2Rc2, S(O)2Rc2, S(O)2NRc2Rc2, NHC(O)Rc2 i N(C14alkil)C(O)Rc2;
svaki Rc2 neovisno jedan od drugoga označava vodik ili skupinu koja se bira između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C36cikloalkil, C46cikloalkenil, phenil, 5-člani do 6-člani heteroaril i 3člani do 7-člani heterociklil;
--
A se bira između fenila i 5-članog do 6-članog heteroarila, ako je F ugljik ili
A je 5-člani do 6-člani heteroaril koji sadrži dušik, ako je F dušik;
svaki R4 se neovisno bira između Ra4 i Rb4;
svaki Ra4 neovisno jedan od drugoga predstavlja skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rb4 i/ili Rc4, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rb4 se neovisno bira između sljedećih: -ORc4, -NRc4Rc4, halogen, CN, C(O)Rc4, C(O)ORc4, C(O)NRc4Rc4, C(O)NRg4ORc4, S(O)2Rc4, S(O)2NRc4Rc4, -NHSO2Rc4, -N(C1-4alkil)SO2Rc4, NHC(O)Rc4 i N(C14alkil)C(O)Rc4;
svaki Rc4 neovisno jedan od drugoga označava vodik ili skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rd4 i/ili Re4, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rd4 se neovisno bira između sljedećih: -ORe4, -NRe4Re4, halogen, CN, C(O)Re4, C(O)ORe4, C(O)NRe4Re4, C(O)NRg4ORe4, S(O)2Re4, S(O)2NRe4Re4, NHC(O)Re4 i N(C14alkil)C(O)Re4;
svaki Re4 neovisno jedan od drugoga označava vodik ili skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rf4 i/ili Rg4, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rf4 se neovisno bira između sljedećih: -ORg4, -NRg4Rg4, halogen, CN, C(O)Rg4, C(O)ORg4, C(O)NRg4Rg4, C(O)NRg4ORg4, S(O)2Rg4, S(O)2NRg4Rg4, NHC(O)Rg4 i N(C14alkil)C(O)Rg4;
svaki Rg4 se neovisno bira između sljedećih: vodik, C1-6alkil, C2-6alkenil, C26alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C6-10aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
r označava broj 0, 1, 2 ili 3;
--
n označava broj 1 ili 2;
--
svaki R7 se neovisno bira između sljedećih: halogen, C1-4alkil, -CN, C14haloalkil, OC1-4alkil i OC1-4haloalkil;
q označava broj 0, 1, 2 ili 3;
--
W, X i Y su –CH= uz uvjet da vodik u svakom –CH= može biti zamijenjen sa supstituentom R7 ako je prisutan;
--
V je kisik ili sumpor;
--
D je dušik, E je ugljik i F je ugljik; ili
D je ugljik, E je dušik i F je ugljik; ili
D je ugljik, E je ugljik i F je dušik;
ili njegova sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom (Ia) ili (Ib) ili (Ic)
[image]
[image]
[image]
ili njegova sol.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom (Ia*) ili (Ib*) ili (Ic*)
[image]
[image]
[image]
ili njegova sol.
4. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da
R1 je skupina, opcionalno supstituirana s jednim ili više, istih ili različitih Rb1 i/ili Rc1, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C16haloalkil, C3-7cikloalkil, C47cikloalkenil, C6-10aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rb1 se neovisno bira između sljedećih: -ORc1, -NRc1Rc1, halogen, CN, C(O)Rc1, C(O)ORc1, C(O)NRc1Rc1, S(O)2Rc1, S(O)2NRc1Rc1, NHC(O)Rc1 i N(C14alkil)C(O)Rc1;
svaki Rc1 neovisno jedan od drugoga označava vodik ili skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rd1 i/ili Re1, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rd1 se neovisno bira između sljedećih: -ORe1, -NRe1Re1, halogen, CN, C(O)Re1, C(O)ORe1, C(O)NRe1Re1, S(O)2Re1, S(O)2NRe1Re1, NHC(O)Re1 i N(C14alkil)C(O)Re1;
svaki Re1 neovisno jedan od drugoga označava vodik ili skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rf1 i/ili Rg1, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rf1 se neovisno bira između sljedećih: -ORg1, -NRg1Rg1, halogen, CN, C(O)Rg1, C(O)ORg1, C(O)NRg1Rg1, S(O)2Rg1, S(O)2NRg1Rg1, NHC(O)Rg1 i N(C14alkil)C(O)Rg1;
svaki Rg1 se neovisno bira između slljedećih: vodik, C1-6alkil, C2-6alkenil, C26alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C6-10aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
ili njegova sol.
5. Spoj prema patentnom zahtjevu 1, naznačen time, da
jedan od R2 i R3 je vodik a drugi se bira između fenila i 5-članog do 6-članog heteroarila, pri čemu su navedeni fenil i 5-člani do 6-člani heteroaril opcionalno supstituirani s jednim ili više, istih ili različitih supstituenata koji se biraju između sljedećih: OC16alkil, halogen, C16alkil i C16haloalkil;
ili njegova sol.
6. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da
R3 jest vodik;
ili njegova sol.
7. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da
A se bira između fenila i 5-članog do 6-članog heteroarila, ako je F ugljik ili
A je 5-člani do 6-člani heteroaril koji sadrži dušik, ako je F dušik;
svaki R4 se neovisno bira između Ra4 i Rb4;
svaki Ra4 neovisno jedan od drugoga predstavlja skupinu, opcionalno supstituiranu s jednim ili više, istih ili različitih Rb4 i/ili Rc4, koji se biraju između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
svaki Rb4 se neovisno bira između sljedećih: -ORc4, -NRc4Rc4, halogen, CN, C(O)Rc4, C(O)ORc4, C(O)NRc4Rc4, C(O)NHORc4, S(O)2Rc4, S(O)2NRc4Rc4, -NHSO2Rc4, -N(C1-4alkil)SO2Rc4, NHC(O)Rc4 i N(C14alkil)C(O)Rc4;
svaki Rc4 neovisno jedan od drugoga se bira između sljedećih: vodik, C1-6alkil, C26alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-člani do 10-člani heteroaril i 3člani do 10-člani heterociklil;
r označava broj 0, 1, 2 ili 3;
ili njegova sol.
8. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da
A zajedno s r supstituenata R4 predstavlja
[image]
;
R8 se bira između sljedećih: vodik, C1-6alkil, -OC1-6alkil, halogen, CN, C(O)OH, C(O)OC16alkil, C(O)NH2, C(O)NHC1-6alkil, C(O)N(C16alkil)2 i S(O)2C16alkil;
R9 se bira između sljedećih: vodik, C1-6alkil, -OC1-6alkil, halogen, CN, C(O)OH, C(O)OC16alkil, C(O)NH2, C(O)NHC1-6alkil, C(O)N(C16alkil)2 i S(O)2C16alkil;
R10 se bira između sljedećih: vodik, C1-6alkil, -OC1-6alkil, halogen, CN, C(O)OH, C(O)OC16alkil, C(O)NH2, C(O)NHC1-6alkil, C(O)N(C16alkil)2 i S(O)2C16alkil;
uz uvjet da najmanje jedan od R8 do R10 ali ne svi od R8 do R10 je/su vodik;
ili njegova sol.
9. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da
svaki R7 je neovisno halogen ili -CN i q je 1 ili 2;
ili njegova sol.
10. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se bira između sljedećih:
[image]
[image]
[image]
[image]
11. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
12. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
13. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
14. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
15. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
16. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
17. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
18. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
19. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
20. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
21. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
22. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
23. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
24. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
25. Spoj prema patentnom zahtjevu 10, naznačen time, da je predstavljen Formulom
[image]
26. Farmaceutski prihvatljiva sol, naznačena time, da je od bilo kojega od spojeva u skladu s bilo kojim od patentnih zahtjeva 11 do 25.
27. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol, naznačeni time, da su za uporabu kao lijek.
28. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol, naznačeni time, da su za uporabu u liječenju i/ili prevenciji bolesti i/ili stanja koji se biraju od sljedećih:
virusne infekcije (primjerice HIV i Kaposijev sarkom); upalne i autoimune bolesti (primjerice kolitis, artritis, Alzheimerova bolest, glomerulonefritis i zacijeljivanje rana); bakterijske, gljivične i/ili parazitne infekcije; leukemije, limfomi i solidni tumori (primjerice karcinomi i sarkomi), kožne bolesti (primjerice psorijaza); bolesti zasnovane na hiperplaziji koje su naznačene time, da se povećava broj stanica (primjerice fibroblasti, hepatociti, koštane stanice i stanice koštane srži, stanice hrskavice ili glatkih mišića ili epitelne stanice (primjerice endometrijska hiperplazija); bolesti kostiju i kardiovaskularne bolesti (primjerice restenoza i hipertrofija); oni su također prikladni za zaštitu proliferacijskih stanica (primjerice kose, crijeva, krvi i progenitorskih stanica) od oštećenja DNA koje je prouzročeno radijacijom, UV obradom i/ili liječenjem citostaticima; tumori na mozgu kao što je na primjer akustični neurinom, astrocitomi kao što su pilocitički astrocitomi, fibrilarni astrocitom, protoplasmički astrocitom, gemistocitarni astrocitom, anaplastični astrocitom i glioblastom, gliom, limfomi mozga, metastaze na mozgu, hipofizalni tumor kao što je prolaktinom, tumor koji proizvodi HGH (ljudski hormon rasta) i tumor koji proizvodi ACTH (adrenokortikotropni hormon), kraniofaringiomi, meduloblastomi, meningeomi i oligodendrogliomi; tumori živaca (neoplazme) kao što su na primjer tumori vegetativnog živčanog sustava kao što je neuroblastom simpatikum, ganglioneurom, paragangliom (feokromocitom, kromafinom) i tumor glomus-karotikum, tumori na perifernom živčanom sustavu kao što jsu amputacijski neurom, neurofibrom, neurinom (neurilemom, Schwannom) i maligni Schwannom, kao i tumori središnjeg živčanog sustava kao što su tumori na mozgu i tumori koštane srži; intestinalni rak kao što je na primjer karcinom rektuma, karcinom debelog crijeva, kolorektalni karcinom, analni karcinom, karcinom velikog crijeva, tumori malog crijeva i duodenuma; tumori očnog kapka kao što je bazaliom ili karcinom bazalnih stanica; rak gušterače ili karcinom pankreasa; rak mokraćnog mjehura ili karcinom mokraćnog mjehura i ostali urotelijalni rakovi; rak pluća (bronhijalni karcinom) kao što su na primjer bronhijalni karcinomi malih stanica (karcinomi zobenih stanica) i bronhijalni karcinomi ne-malih stanica (NSCLC) kao što su karcinomi pločastih epitela, adenokarcinomi i bronhijalni karcinomi velikih stanica; rak dojke kao što je primjerice karcinom mliječnih žlijezda kao što su infiltrirani duktalni karcinom, koloidni karcinom, lobularni invazivni karcinom, tubularni karcinom, adenocistični karcinom i papilarni karcinom, rak dojke pozitivan na hormonski receptor (rak dojke pozitivan na estrogenski receptor, rak dojke pozitivan na progesteronski receptor), rak dojke pozitivan na Her2, trostruko negativni rak dojke; ne-Hodgkinovi limfomi (NHL) kao što su primjerice Burkittov limfom, ne-Hodgkinov limfom niske malignosti (NHL) i mukozni fungoidi; rak maternice ili endometrijski karcinom ili karcinom korpusa; CUP sindrom (prema engl. Cancer of Unknown Primary – rak nepoznatog izvora); rak jajnika ili karcinom jajnika kao što je mucinozni, endometrijski ili serozni rak; rak žučnog mjehura; rak žučnih vodova kao što je primjerice Klatskinov tumor; rak testisa kao što su na primjer seminomi i ne-seminomi; limfom (limfosarkom) kao što su primjerice maligni limfom, Hodgkinova bolest, ne-Hodgkinovi limfomi (NHL) kao što su kronična limfocitna leukemija, leukemijska retikuloendotelioza, imunocitom, plazmocitom, multipli mijelom (MM), imunoblastom, Burkittov limfom, mukozni fungoidi T-zone, anaplastični limfoblastom velikih stanica i limfoblastom; rak grkljana kao što su primjerice tumori glasnica, supraglotidni, glotidni i subglotidni tumori grkljana; rak kostiju kao što su na primjer osteohondrom, hondrom, hondroblastom, hondromiksoidni fibrom, osteom, osteoidni osteom, osteoblastom, eozinofilni granulom, tumor divovske stanice, hondrosarkom, osteosarkom, Ewingov sarkom, retikulo-sarkom, sarkom mekog tkiva, liposarkom, plazmocitom, fibrozna displazija, mladenačke ciste na kostima i aneurizmatične ciste kostiju; tumori glave i vrata kao što su na primjer tumori usana, jezika, dna usta, usne šupljine, desni, nepca, žlijezde slinovnice, grla, nosne šupljine, paranazalnih sinusa, grkljana i srednjeg uha; rak jetre kao što su primjerice karcinom jetrenih stanica ili hepatocelularni karcinom (HCC); leukemije, kao što su na primjer akutne leukemije kao primjerice akutna limfocitna / limfoblastična leukemija (ALL), akutna mijeloična leukemija (AML); kronične leukemije kao što su kronična limfocitna leukemija (CLL), kronična mijeloična leukemija (CML); mijelodisplastični sindromi (MDS); rak želuca ili gastrički karcinom kao što su primjerice papilarni, tubularni i mucinozni adenokarcinom, karcinom prstenastih stanica s pečatom, adenoskvamozni karcinom, karcinom malih stanica i nediferencirani karcinom; melanomi kao što su primjerice površinski rasprostranjeni, čvorasti, lentigo-maligna i akralni lentigni melanom; rak bubrega kao što su na primjer karcinom bubrežnih stanica ili hipernefrom ili Grawitzov tumor; rak jednjaka ili karcinom jednjaka; rak penisa; rak prostate (primjerice rak prostate otporan na kastraciju); rak grla ili karcinomi ždrijela kao što su na primjer karcinomi nazofarinksa, karcinomi orofarinksa i karcinomi hipofarinksa; retinoblastom, vaginalni rak ili vaginalni karcinom, mezoteliom; karcinomi pločastih epitela, adenokarcinomi, in situ karcinomi, maligni melanomi i sarkomi; tiroidni karcinomi kao što su primjerice papilarni, folikularni i medularni karcinom štitnjače, kao i anaplastični karcinomi; spinaliom, epidermoidni karcinom i karcinom pločastih epitela kože; timomi, rak uretre, rak cerviksa, adenoidni cistični karcinom (AdCC), adrenokortikalni karcinom i rak vulve.
29. Spoj za uporabu prema patentnom zahtjevu 28, naznačen time, da je za uporabu u liječenju i/ili prevenciji raka pluća koji se bira iz skupine koju čine bronhijalni karcinomi malih stanica i bronhijalni karcinomi ne-malih stanica (NSCLC) kao što su karcinomi pločastih epitelnih stanica, adenokarcinomi i bronhijalni karcinomi velikih stanica.
30. Spoj za uporabu prema patentnom zahtjevu 28, naznačen time, da je za uporabu u liječenju i/ili prevenciji bolesti ili stanja koji se biraju iz skupine koju čine sarkom mekog tkiva i liposarkom.
31. Spoj za uporabu prema patentnom zahtjevu 28, naznačen time, da je za uporabu u liječenju i/ili prevenciji tumora na mozgu koji se bira iz skupine koju čine akustični neurinom, astrocitomi, glioblastom, gliom, limfomi mozga, metastaze na mozgu, hipofizni tumor kao što je prolaktinom, tumor koji proizvodi HGH i tumor koji proizvodi ACTH, kraniofaringiomi, meduloblastomi, meningeomi i oligodendrogliomi.
32. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol, naznačeni time, da su za uporabu u liječenju i/ili prevenciji raka, zaraza, upala ili autoimunih bolesti.
33. Spoj ili njegova farmaceutski prihvatljiva sol, za uporabu prema patentnom zahtjevu 28, naznačeni time, da su za liječenje raka.
34. Farmaceutski pripravak, naznačen time, da sadrži najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač.
35. Farmaceutski pripravak, naznačen time, da sadrži najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol, i najmanje jednu, neku drugu citostatičku i/ili citotoksičnu aktivnu tvar.
36. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol, koji su za uporabu u liječenju i/ili prevenciji raka, zaraza, upala ili autoimunih bolesti, naznačeni time, da se navedeni spoj primjenjuje prije, poslije ili zajedno s najmanje jednom, nekom drugom citostatičkom ili citotoksičnom aktivnom tvari.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15189210 | 2015-10-09 | ||
EP16778038.6A EP3359542B1 (en) | 2015-10-09 | 2016-10-07 | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
PCT/EP2016/074008 WO2017060431A1 (en) | 2015-10-09 | 2016-10-07 | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210960T1 true HRP20210960T1 (hr) | 2021-09-03 |
Family
ID=54292702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210960TT HRP20210960T1 (hr) | 2015-10-09 | 2021-06-15 | Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53 |
Country Status (32)
Country | Link |
---|---|
US (3) | US10144739B2 (hr) |
EP (1) | EP3359542B1 (hr) |
JP (1) | JP6602470B2 (hr) |
KR (1) | KR20180058832A (hr) |
CN (2) | CN113214270A (hr) |
AR (1) | AR106314A1 (hr) |
AU (1) | AU2016333721B2 (hr) |
BR (1) | BR112018007155B1 (hr) |
CA (1) | CA3000063A1 (hr) |
CL (1) | CL2018000666A1 (hr) |
CO (1) | CO2018003565A2 (hr) |
CY (1) | CY1124284T1 (hr) |
DK (1) | DK3359542T3 (hr) |
EA (1) | EA036013B1 (hr) |
ES (1) | ES2873895T3 (hr) |
HK (1) | HK1252365A1 (hr) |
HR (1) | HRP20210960T1 (hr) |
HU (1) | HUE054985T2 (hr) |
IL (1) | IL258073B (hr) |
LT (1) | LT3359542T (hr) |
MA (1) | MA50065B1 (hr) |
MX (1) | MX2018004207A (hr) |
PE (1) | PE20181205A1 (hr) |
PH (1) | PH12018500763A1 (hr) |
PL (1) | PL3359542T3 (hr) |
PT (1) | PT3359542T (hr) |
RS (1) | RS61936B1 (hr) |
SA (1) | SA518391307B1 (hr) |
SI (1) | SI3359542T1 (hr) |
TW (1) | TWI737635B (hr) |
UA (1) | UA123905C2 (hr) |
WO (1) | WO2017060431A1 (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
EP3183254B1 (en) | 2014-08-21 | 2019-05-22 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
JP6602470B2 (ja) * | 2015-10-09 | 2019-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mdm2−p53阻害薬としてのスピロ[3h−インドール−3,2‘−ピロリジン]−2(1h)−オン化合物及び誘導体 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
BR112019021032A2 (pt) * | 2017-04-05 | 2020-05-05 | Boehringer Ingelheim Int | terapia combinada anticâncer |
EA202091583A1 (ru) * | 2017-12-29 | 2020-10-08 | Ган Энд Ли Фармасьютикалз | Соединения, которые могут применяться в качестве ингибитора опухоли, способ их получения и их применение |
EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
US20210324478A1 (en) * | 2018-07-18 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators |
US10590147B1 (en) | 2019-09-10 | 2020-03-17 | King Saud University | Spirooxindole-pyrrolothiazole heterocyclic hybrids |
KR20220098755A (ko) * | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
KR20230019462A (ko) | 2020-06-02 | 2023-02-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CN112047951A (zh) * | 2020-10-16 | 2020-12-08 | 吉林大学 | 手性螺[吡咯-2,2’-呋喃]化合物及其制备方法 |
IL310121A (en) | 2021-08-09 | 2024-03-01 | Boehringer Ingelheim Int | A preparation for oral administration that includes an MDM2-antagonist for the treatment of cancer |
WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202337431A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114540A (en) | 1997-09-08 | 2000-09-05 | Arqule, Inc. | Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use |
EA019566B1 (ru) | 2005-02-22 | 2014-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 |
JP2006234861A (ja) | 2005-02-22 | 2006-09-07 | Fujinon Sano Kk | 光学ガラスの製造方法,偏光変換素子の製造方法及び偏光変換素子 |
CA2598956A1 (en) | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
ATE495176T1 (de) | 2006-03-13 | 2011-01-15 | Hoffmann La Roche | Spiroindolinon-derivate |
CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
JP5399904B2 (ja) | 2006-08-30 | 2014-01-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Mdm2の小分子阻害剤およびその使用 |
AR065860A1 (es) | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8134001B2 (en) | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
US20100190814A1 (en) | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
NZ600430A (en) * | 2009-11-12 | 2014-06-27 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
US20120071499A1 (en) * | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
EA201390682A1 (ru) | 2010-11-12 | 2014-01-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
US20130053410A1 (en) | 2011-03-03 | 2013-02-28 | David Joseph Bartkovitz | Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione |
MY172862A (en) | 2011-03-10 | 2019-12-13 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
JP2014513699A (ja) | 2011-05-11 | 2014-06-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | スピロ−オキシインドールmdm2アンタゴニスト |
CN102443004A (zh) * | 2011-11-01 | 2012-05-09 | 南京工业大学 | 有机发光材料6,7,14,15-四氢-5,13-二取代苯并[1,2-c:4,5-c’]二吖啶类化合物、合成方法及应用 |
CN103910746B (zh) * | 2014-02-28 | 2016-08-03 | 中山大学 | 一类海洋真菌来源的Berkeleyones化合物及其制备方法和应用 |
WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
WO2016001376A1 (en) * | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
EP3183254B1 (en) | 2014-08-21 | 2019-05-22 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
NO2721710T3 (hr) | 2014-08-21 | 2018-03-31 | ||
JP6602470B2 (ja) * | 2015-10-09 | 2019-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mdm2−p53阻害薬としてのスピロ[3h−インドール−3,2‘−ピロリジン]−2(1h)−オン化合物及び誘導体 |
JP2018017594A (ja) * | 2016-07-27 | 2018-02-01 | セイコーエプソン株式会社 | 動力伝達装置、ロボットおよびプリンター |
-
2016
- 2016-10-07 JP JP2018517748A patent/JP6602470B2/ja active Active
- 2016-10-07 US US15/287,958 patent/US10144739B2/en active Active
- 2016-10-07 PL PL16778038T patent/PL3359542T3/pl unknown
- 2016-10-07 CA CA3000063A patent/CA3000063A1/en active Pending
- 2016-10-07 WO PCT/EP2016/074008 patent/WO2017060431A1/en active Application Filing
- 2016-10-07 EA EA201890888A patent/EA036013B1/ru not_active IP Right Cessation
- 2016-10-07 DK DK16778038.6T patent/DK3359542T3/da active
- 2016-10-07 MX MX2018004207A patent/MX2018004207A/es active IP Right Grant
- 2016-10-07 LT LTEP16778038.6T patent/LT3359542T/lt unknown
- 2016-10-07 PE PE2018000507A patent/PE20181205A1/es unknown
- 2016-10-07 AU AU2016333721A patent/AU2016333721B2/en active Active
- 2016-10-07 ES ES16778038T patent/ES2873895T3/es active Active
- 2016-10-07 PT PT167780386T patent/PT3359542T/pt unknown
- 2016-10-07 RS RS20210700A patent/RS61936B1/sr unknown
- 2016-10-07 KR KR1020187013102A patent/KR20180058832A/ko not_active Application Discontinuation
- 2016-10-07 CN CN202110322485.6A patent/CN113214270A/zh active Pending
- 2016-10-07 MA MA50065A patent/MA50065B1/fr unknown
- 2016-10-07 TW TW105132652A patent/TWI737635B/zh active
- 2016-10-07 AR ARP160103098A patent/AR106314A1/es unknown
- 2016-10-07 BR BR112018007155-2A patent/BR112018007155B1/pt active IP Right Grant
- 2016-10-07 CN CN201680058768.1A patent/CN108137590B/zh active Active
- 2016-10-07 SI SI201631182T patent/SI3359542T1/sl unknown
- 2016-10-07 HU HUE16778038A patent/HUE054985T2/hu unknown
- 2016-10-07 UA UAA201804904A patent/UA123905C2/uk unknown
- 2016-10-07 EP EP16778038.6A patent/EP3359542B1/en active Active
-
2018
- 2018-03-13 IL IL258073A patent/IL258073B/en active IP Right Grant
- 2018-03-13 CL CL2018000666A patent/CL2018000666A1/es unknown
- 2018-04-04 CO CONC2018/0003565A patent/CO2018003565A2/es unknown
- 2018-04-06 PH PH12018500763A patent/PH12018500763A1/en unknown
- 2018-04-09 SA SA518391307A patent/SA518391307B1/ar unknown
- 2018-06-08 US US16/003,232 patent/US10717742B2/en active Active
- 2018-09-11 HK HK18111661.5A patent/HK1252365A1/zh unknown
-
2020
- 2020-04-09 US US16/844,473 patent/US10882866B1/en active Active
-
2021
- 2021-06-14 CY CY20211100524T patent/CY1124284T1/el unknown
- 2021-06-15 HR HRP20210960TT patent/HRP20210960T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210960T1 (hr) | Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53 | |
JP7189956B2 (ja) | Sos1阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体 | |
HRP20200854T1 (hr) | Novi biciklički inhibitori bromodomene | |
EA202092320A1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
ES2873515T3 (es) | Derivado de quinolona, sal o estereoisómero del mismo farmacéuticamente aceptable, como inhibidor de AXL | |
KR100737259B1 (ko) | 이미다조[1,2-a]피리딘 및 피라졸로[2,3-a]피리딘 유도체 | |
JP5997763B2 (ja) | タンパク質キナーゼ阻害剤としての大環状化合物 | |
WO2019018584A1 (en) | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | |
EA201992418A1 (ru) | Бициклические соединения и их применение в лечении рака | |
AR108223A1 (es) | Derivados de 6-oxo-1,6-dihidro-piridin-3-il | |
JP6487925B2 (ja) | セリン/トレオニンキナーゼ阻害剤 | |
JP2020504742A (ja) | 新規のベンジルアミノ置換キナゾリンおよびsos1阻害剤としての誘導体 | |
US20220144810A1 (en) | New isoindolinone substituted indoles and derivatives as ras inhibitors | |
BR112020015431A2 (pt) | Compostos heterocíclicos como inibidores de quinase | |
JOP20210317A1 (ar) | مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان | |
JP2011510995A5 (hr) | ||
AU2018269667B2 (en) | N-substituted indole derivatives | |
HRP20211652T1 (hr) | Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze | |
CR20210409A (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
CA3173602A1 (en) | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors | |
JOP20210172A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
CN115551500A (zh) | 4-氨基丁-2-烯酰胺衍生物及其盐 | |
JP2023512175A (ja) | HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン | |
PT1928887E (pt) | Métodos de preparação de análogos de quinolona | |
BR112019009432A2 (pt) | compostos de pirimidina ou sal famaceitucamente aceitável, método de preparo dos mesmos, e composição farmacêutica e comida funcional saudável |